Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Dirk Dressler

Showing results (21-30 of 160) with videos related to

Pageof 16
Sort By:
Journal of Neural Transmission (Vienna, Austria : 1996)|August 4, 2017
Long-term stability of reconstituted incobotulinumtoxinA: how can we reduce costs of botulinum toxin therapy?Dirk Dressler, Hans Bigalke
European Neurology|October 14, 2004
Antibody-induced failure of botulinum toxin type B therapy in de novo patientsDirk Dressler, Hans Bigalke
Journal of Neurology|March 12, 2005
Botulinum toxin type B de novo therapy of cervical dystonia: frequency of antibody induced therapy failureDirk Dressler, Hans Bigalke
Movement Disorders : Official Journal of the Movement Disorder Society|February 9, 2002
Botulinum toxin antibody type A titres after cessation of botulinum toxin therapyDirk Dressler, Hans Bigalke
Advances in Neurology|September 27, 2003
Autonomic side effects of botulinum toxin type B therapyDirk Dressler, Reiner Benecke
Disability and Rehabilitation|November 23, 2007
Botulinum toxin treatment of axial and cervical dystoniaReiner Benecke, Dirk Dressler
Journal of Neural Transmission (Vienna, Austria : 1996)|April 1, 2026
Botulinum Toxin: Preclinical and Clinical AspectsDirk Dressler, Jürgen Frevert
Journal of Neural Transmission (Vienna, Austria : 1996)|January 12, 2026
The mouse diaphragm assay in botulinum toxin therapyPawel Tacik, Dirk Dressler
Journal of Neural Transmission (Vienna, Austria : 1996)|January 22, 2026
Obituary: Hans Bigalke 1946-2024Dirk Dressler, Jürgen Frevert
Biologics : Targets & Therapy|January 7, 2011
Complexing proteins in botulinum toxin type A drugs: a help or a hindrance?Jürgen Frevert, Dirk Dressler
Pageof 16

Showing results (21-30 of 160) with videos related to

Sort By:
Pageof 16
Journal of Neural Transmission (Vienna, Austria : 1996)|August 4, 2017
Long-term stability of reconstituted incobotulinumtoxinA: how can we reduce costs of botulinum toxin therapy?Dirk Dressler, Hans Bigalke
European Neurology|October 14, 2004
Antibody-induced failure of botulinum toxin type B therapy in de novo patientsDirk Dressler, Hans Bigalke
Journal of Neurology|March 12, 2005
Botulinum toxin type B de novo therapy of cervical dystonia: frequency of antibody induced therapy failureDirk Dressler, Hans Bigalke
Movement Disorders : Official Journal of the Movement Disorder Society|February 9, 2002
Botulinum toxin antibody type A titres after cessation of botulinum toxin therapyDirk Dressler, Hans Bigalke
Advances in Neurology|September 27, 2003
Autonomic side effects of botulinum toxin type B therapyDirk Dressler, Reiner Benecke
Disability and Rehabilitation|November 23, 2007
Botulinum toxin treatment of axial and cervical dystoniaReiner Benecke, Dirk Dressler
Journal of Neural Transmission (Vienna, Austria : 1996)|April 1, 2026
Botulinum Toxin: Preclinical and Clinical AspectsDirk Dressler, Jürgen Frevert
Journal of Neural Transmission (Vienna, Austria : 1996)|January 12, 2026
The mouse diaphragm assay in botulinum toxin therapyPawel Tacik, Dirk Dressler
Journal of Neural Transmission (Vienna, Austria : 1996)|January 22, 2026
Obituary: Hans Bigalke 1946-2024Dirk Dressler, Jürgen Frevert
Biologics : Targets & Therapy|January 7, 2011
Complexing proteins in botulinum toxin type A drugs: a help or a hindrance?Jürgen Frevert, Dirk Dressler
Pageof 16